Two other classes of anti-diabetic drugs, namely meglitinides [51] and GLP-1 receptor agonists [52], have been tried in patients with HNAF1A-MODY with promising results and with a lower risk of hypoglycemia compared to sulfonylureas. Here, GLP1R is linked to MODY.